Immunization of infants

Details Immunization of infants Immunization of infants

1996-11-22

2001-03-20

Priebe, Scott D. (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S069100, C435S375000

Reexamination Certificate

active

06204250

ABSTRACT:

1. INTRODUCTION
The present invention relates to methods and compositions which may be used to immunize infant mammals against a target antigen, wherein an immunogenically effective amount of a nucleic acid encoding a relevant epitope of a desired target antigen is administered to the infant.
2. BACKGROUND OF THE INVENTION
A properly operating immune system enables an organism to maintain a healthy status quo by distinguishing between antigens associated with the organism itself, which are allowed to persist, and antigens associated with disease, which are disposed of. Decades ago, Burnet proposed that the immune system's ability to distinguish between “self” and “non-self” antigens results from the elimination of self-reactive lymphocytes in the developing organism (Burnet, 1959
, The Clonal Selection Theory of Acquired Immunity
, Vanderbilt Univ. Press, Nashville, Tenn.). The phenomenon wherein an organism loses the ability to produce an immune response toward an antigen is referred to as “tolerance”.
Over the years, a number of observations consistent with the clonal selection theory of tolerance have been documented. For example, genetically non-identical twin cattle, which share a placenta and are exposed to each other's blood cells in utero, fail to reject the allogeneic cells of their sibling as adults (Owen, 1945, Science 102:400). As another example, adult rodents that had been injected, at birth, with hemopoietic cells from a genetically distinct donor rodent strain were able to accept tissue transplants from that donor strain (Billingham et al., 1953, Nature 172:603; Billingham, 1956, Proc. R. Soc. London Ser. B. 239:44). However, in the early 1980's it was shown that the injection of minute amounts of antigen (namely an immunoglobulin expressing A48 regulatory idiotype) induced the expansion of helper T cells (Rubinstein et al., 1982, J. Exp. Med. 156:506-521).
The concept of tolerization is associated with the traditional belief that neonates are themselves incapable of mounting an effective immune response. It has been generally believed that neonates rely on maternal antibodies (passively transferred via the placenta) for immunity, until the neonate begins to synthesize its own IgG anti-bodies (at about 3-4 months after birth, in humans; Benjamini and Leskowitz, 1988, “Immunology, A Short Course”, Alan R. Liss, Inc., New York, p. 65). In spite of the fact that passive immunity still plays a dominant role until 6-8 months after birth, the immune system gradually acquires the ability to mount adult-like immune responses.
More recently, several groups have reported findings that dispute the hypothesis that exposure to an antigen in early life disarms the ability of the immune system to react to that antigen.
Forsthuber et al. (1996, Science 271:1728-1730; “Forsthuber”) suggest that the impaired lymph node response of so-called “tolerized” mice was an artifact caused by a technical inability to assess immune function. They reported that neonatal mice, injected with hen egg lysozyme (HEL) in Freund's incomplete adjuvant (“IFA”) according to a protocol considered to induce tolerance in adults as well as neonates, displayed an impaired response in the lymph nodes consistent with tolerization. However, the spleen cells of these mice reportedly proliferated vigorously in response to HEL, a response previously unmeasurable due to technical limitations. The authors propose that neonatal injection did not tolerize, but rather induced functional memory cells that were detectable in spleen but not lymph nodes.
Sarzotti et al. (1996, Science 271:1726; “Sarzotti”) report that inoculation of newborn mice with a high dose of Cas-Br-M murine leukemia virus (“Cas”) does not result in immunological unresponsiveness, but rather leads to a nonproductive type 2 response which is likely to have a negative effect on the induction of mature effector cells. According to Sarzotti, clonal deletion of relevant CTL was not observed in mice infected at birth with a low dose of Cas.
Finally, Ridge et al. (1996, Science 271:1723-1726; “Ridge”) proposes that previous reports of tolerance induction may have been associated with a relative paucity of antigen presenting cells. Ridge observed the induction of CTL reactivity in neonatal mice injected with antigen expressed on dendritic cells (which are so-called professional antigen presenting cells).
The use of nucleic acids as vaccines was known prior to the present invention (see, for example, International Application Publication No. WO 94/21797, by Merck & Co. and Vical, Inc., and International Application Publication No. WO 90/11092). It was not known, however, that such vaccines could be used to induce an immune response, including humoral and cellular components, in infant mammals.
3. SUMMARY OF THE INVENTION
The present invention relates to methods and compositions which may be used to immunize infant mammals against a target antigen, wherein an immunogenically effective amount of a nucleic acid encoding a relevant epitope of a desired target antigen is administered to the infant. It is based, at least in part, on the discovery that such genetic immunization of infant mammals could give rise to effective cellular (including the induction of cytotoxic T lymphocytes) and humoral immune responses against target antigen. Moreover, the present invention may reduce the need for subsequent boost administrations (as are generally required for protein and killed pathogen vaccines), and may prevent side-effects associated with live attenuated vaccines. For instance, the World Health Organization recommends waiting nine months after birth before immunizing against rubella, measles, and mumps, in order to avoid undesirable side effects associated with vaccination against these diseases. Similarly, the World Health Organization recommends waiting two months after birth before immunizing children against influenza virus. In addition to concern over side effects, there is doubt as to whether an effective immune response may be generated using these conventional vaccines prior to the recommended ages.


REFERENCES:
patent: 5589466 (1996-12-01), Felgner et al.
patent: 9011092 (1990-10-01), None
patent: 9421797 (1994-09-01), None
Orkin et al. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,” NIH Report and Recommendation, Dec. 7, 1995.*
Marshall, E. “Gene Therapy's Growing Pains,” Science, vol. 269: 1050-1055, Aug. 25, 1995.*
Mulligan, R.C. “The Basic Science of Gene Therapy,” Science, vol. 260: 926-932, May 14, 1993.*
Miller et al., “Targeted vectors for Gene Therapy,” FASEB J., vol. 9: 190-199, Feb. 1995.*
Verma et al., “Gene Therapy-Promises, Problems, and Prospects,” Nature, vol. 389: 239-242, Sep. 18, 1997.*
Ulmer et al., “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein,” Science, vol. 259: 1745-1748, Mar. 19, 1993.*
Pedroza et al., “DNA Vaccination against Persistent Viral Infection,” J. of Virology, vol. 69: 2574-2582, Apr. 1995.*
Kuzu et al., “In vivo priming effect during various stages of ontogeny of an influenza A virus nucleoprotein peptide,” Eur. J. Immunol., vol. 23: 1397-1400, Jun. 1993.*
Bot et al., “DNA Immunization of Newborn Mice with a Plasmid-Expressing Nucleoprotein of Influenza Virus,” Viral Immunology, vol. 9: 207-210, Oct. 1996.*
Bachmann et al, Current Opinion in Immunology, vol. 6:320-326, 1994.*
Davis et al, “DNA-based immunization” Molecular and Cell Biology of Human Disease Series, vol. 5: 368-387, 1995.*
Lai et al, “Use of the hepatitis B recombinant DNA yeast vaccine (H-B-Vax II) in children: two doses vs three doses of 5 micrograms regime; an interim report,” J. of Infection, vol. 13, Suppl. A: 19-25, Jul. 1986.*
Lai et al. “Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs plasma-derived vaccine in children: immunogenicity and anamnestic responses,” Hepatology, vol. 18: 763-767, Oct. 1993.*
Assateerawatt et al. “Immunogenicity and efficacy of a recombinant DNA hep

Affiliated with

Also associated with

Rating

Immunization of infants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunization of infants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunization of infants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2516451